Podcast: The Future Of R&D Is Self-Driving

In this episode of the In Vivo podcast, visionary University of Toronto researcher Alan Aspuru-Guzik talks about the value of generative AI, automation and quantum computing in drug discovery. 

In Vivo Podcast
• Source: Shutterstock

Alan Aspuru-Guzik has managed, at a young age, to co-found four tech/biotech startups, is professor of chemistry and computer science at the University of Toronto, and sits on the boards of AI-driven biotech, Insilico Medicine. It would be challenging to identify his main project, as he is also chair of Toronto’s Vector Institute for Artificial Intelligence and director of Acceleration Consortium, two projects meant to guide the roll out of artificial intelligence safely and effectively, across a swath of industrial sectors and by a range of global stakeholders.

In this episode of the In Vivo podcast, Alan focuses on the value of generative AI, automation and quantum computing in drug discovery.

Timestamp:

Intro

1:20 - Aspuru-Guzik’s academic and career trajectory

3:40 - Generative AI for molecule creation

6:30 - Intrepid Labs: a self-driving lab that combines automation with machine learning to optimize drug formulation

11:10 - Collaborations with pharma, including work with Insilico Medicine

13:40 - The creative potential of generative AI in drug discovery

16:20 - Quantum computing and pharma

19:30 - Combining quantum power with the self-driving lab

22:00 - Ethics in pharma

26:30 - The future of drug discovery and development

More from Innovation

Trojan Bio Eyes Perfect Rainbow Shot With Immune System Cancer Innovations

 
• By 

Trojan Bio’s proprietary platform, based on engineered antibodies that activate the immune system to fight cancer in the same way as common viral infections, won Biomed Israel's 2025 biopharma start-up award. CEO and cofounder Anat Burkovitz said the technology is attracting investors' attention.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Podcast: Acuitas CSO On CRISPR Delivery Breakthrough And Next-Gen Lipid Nanoparticle Technology

 
• By 

In Vivo sits down with Ying Tam, CSO at Acuitas Therapeutics, to discuss the company's role in delivering the first personalized CRISPR treatment to an infant and the clinical implications of new lipid nanoparticle technologies.

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.